Bryan Selby
Corporate Officer/Principal chez LYELL IMMUNOPHARMA, INC.
Profil
Bryan Selby is currently working as the Senior VP-Clinical Development Operations at Lyell Immunopharma, Inc. Prior to his current position, he held various roles including Director-Statistical Programming at ALZA Corp., Nuvelo, Inc., InterMune, Inc., and Corgentech, Inc. He also served as the Vice President-Biometrics at Medivation LLC (California).
From 2016 to 2023, he worked as the Senior Vice President-Product Development at Myovant Sciences Ltd.
Mr. Selby completed his graduate degree at Kansas State University and his undergraduate degree at Washburn University.
Postes actifs de Bryan Selby
| Sociétés | Poste | Début |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Corporate Officer/Principal | 01/06/2023 |
Anciens postes connus de Bryan Selby
| Sociétés | Poste | Fin |
|---|---|---|
| MYOVANT SCIENCES LTD. | Corporate Officer/Principal | 01/01/2023 |
| INTERMUNE INC | Corporate Officer/Principal | - |
| Corgentech, Inc. | Corporate Officer/Principal | - |
| Nuvelo, Inc. | Corporate Officer/Principal | - |
| ALZA CORPORATION | Corporate Officer/Principal | - |
Formation de Bryan Selby
| Washburn University | Undergraduate Degree |
| Kansas State University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Medivation LLC (California)
 Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Medivation LLC engages in the development and commercialization of novel therapies to treat serious diseases for which there are limited treatment options. The company was founded by Clarence Patrick Machado and David T. Hung in 2004 and is headquartered in San Francisco, CA. | Health Technology |
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
| Nuvelo, Inc. | Health Technology |
| Corgentech, Inc. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
